Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-26-092838
Filing Date
2026-08-07
Accepted
2026-08-07 20:00:09
Documents
1
Period of Report
2026-08-05

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2622546-1_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm2622546-1_4seq1.xml 4 7447
  Complete submission text file 0001104659-26-092838.txt   8985
Mailing Address 1 LETTERMAN DRIVE BUILDING B SAN FRANCISCO CA
Business Address 1 LETTERMAN DRIVE BUILDING B SAN FRANCISCO CA 650-394-5230
Apogee Therapeutics, Inc. (Issuer) CIK: 0001974640 (see all company filings)

EIN.: 934958665 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address
Dambkowski Carl (Reporting) CIK: 0001983476 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41740 | Film No.: 261255909